Atlas Trials

Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer

Clinical trial NCT01501669 · UNKNOWN

Trial details

NCT number
NCT01501669
Sponsor
National Cancer Center, Korea
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2011-06-01
Primary completion
2014-02-01
Enrollment
222

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.